Lenalidomide,Bortezomib,Dexamethasone
Takeda
congress #ims2022 | paul richardson reports data on the phase iii determination trial of rvd asct with r maintenance to progression in patients with newly diagnosed #mm. rvd+asct offers improved pfs vs rvd-alone (82.2 vs 53.2 months) #medicalcongress 
The Multiple Myeloma (MM) Hub is an online educational resource run in collaboration with the European School of Haematology @ESHaematology #mmsm #myeloma